Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Rare Diseases

Lung Neoplasms

Small Cell Lung Carcinoma

Carcinoma

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

Small Cell Lung Cancer

Antineoplastic Agents

All Drugs and Chemicals

Topotecan

AMG 757

Amrubicin

Topoisomerase I Inhibitors

Enzyme Inhibitors

Participants will receive tarlatamab as an intravenous (IV) infusion.

Participants will receive treatment per local standard of care (SOC).

Tarlatamab will be administered as an IV infusion.

Tarlatamab

Lurbinectedin will be administered per local SOC.

Lurbinectedin

Topotecan will be administered per local SOC.

Amrubicin will be administered per local SOC.

Amgen Call Center

The main objective is to compare the efficacy of tarlatamab with standard of care (SOC) on prolonging overall survival (OS).

Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer

A Randomized, Open-label, Phase 3 Study of Tarlatamab Compared With Standard of Care in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy

De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Amgen

Etoposide

Durvalumab

Etoposide phosphate

Antineoplastic Agents, Immunological

Participants will receive tarlatamab once every 2 weeks (Q2W) and durvalumab once every 4 weeks (Q4W).

Participants will receive durvalumab Q4W alone.

The primary objective of this study is to compare the efficacy of tarlatamab plus durvalumab with durvalumab alone on prolonging overall survival (OS).

Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab

A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects With Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (DeLLphi-305)

De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Immunomodulating Agents

Tarlatamab will be administered as a 60-minute intravenous infusion with 1 mg step dose on cycle 1 day 1 followed by a 10 mg target dose on cycle 1 day 8 and cycle 1 day 15 in a 28-day cycle. Subsequent doses (10 mg) will be administered every 2 weeks.

The primary objective of the study is to provide expanded access to and characterize the safety profile of tarlatamab in participants with advanced small cell lung cancer (SCLC) after two or more prior lines of treatment (including at least one platinum-based regimen).

Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer

A Phase 3b, Multicenter, Single-arm, Expanded Access Protocol of Tarlatamab (AMG 757) for the Treatment of Subjects With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment

The recommended phase 2 target dose (RP2D) of tarlatamab in combination with AMG 404 will be estimated using a modified toxicity probability interval (mTPI-2) design. A combination RP2D may be identified based on emerging safety, efficacy, and pharmacodynamic data prior to reaching an maximum tolerated dose (MTD).

Participants will receive the RP2D of tarlatamab in combination with AMG 404 identified in Phase 1 (dose exploration) of the study.

Tarlatamab will be administered as an intravenous (IV) infusion.

AMG 404 will be administered as an intravenous (IV) infusion.

AMG 404

The main purpose of this study is to evaluate the safety, tolerability, and recommended phase 2 target dose of tarlatamab in combination with AMG 404.

AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC)

A Phase 1b Study Evaluating the Safety and Efficacy of AMG 757 in Combination With AMG 404 in Subjects With Small Cell Lung Cancer (SCLC)

Participants will receive tarlatamab on Cycle 1 Day 1, 8 and 15, and once every 2 weeks (Q2W) thereafter (cycle is 28 days).

Participants will receive placebo on Cycle 1 Day 1, 8 and 15, and Q2W thereafter (cycle is 28 days).

Placebo

The primary objective of this study is to compare the efficacy of tarlatamab with placebo as assessed by progression free survival (PFS).

Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Who Have Not Progressed Following Concurrent Chemoradiation Therapy

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer	NCT05740566	Small Cell Lung...	Tarlatamab Lurbinectedin Topotecan Amrubicin	18 Years -	Amgen
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab	NCT06211036	Extensive-Stage... Small-Cell Lung...	Tarlatamab Durvalumab	18 Years - 99 Years	Amgen
Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer	NCT06064500	Small Cell Lung...	Tarlatamab	18 Years -	Amgen
AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC)	NCT04885998	Small Cell Lung...	Tarlatamab AMG 404	18 Years -	Amgen
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)	NCT06117774	Limited Stage S... Small Cell Lung...	Tarlatamab Placebo	18 Years -	Amgen
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab	NCT06211036	Extensive-Stage... Small-Cell Lung...	Tarlatamab Durvalumab	18 Years - 99 Years	Amgen

Spots Global Cancer Trial Database for amg 757

Every month we try and update this database with for amg 757 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for amg 757

Every month we try and update this database with for amg 757 cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for amg 757 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.